FDA Approves New Dosing Guidelines for Afrezza Inhaled Insulin
MannKind (MNKD) receives FDA approval for updated Afrezza dosing recommendations, making it easier for patients to switch from insulin injections to inhaled insulin therapy.
/ 906 items
#Healthcare↓
Merck Ends Talks to Buy Cancer Biotech Revolution Medicines in $30B Deal
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.
Fairmount Funds Sells $133.5M Stake in Apogee Therapeutics
Apogee Therapeutics stock drops 12% after major investor Fairmount Funds Management sells 1.75 million shares worth $133.5 million, significantly reducing its position.
Leerink Upgrades Relmada Therapeutics With $8 Price Target
Leerink starts coverage on Relmada Therapeutics, upgrades the stock to Outperform, and highlights strong potential for its bladder cancer program NDV-01.
Bausch Health’s Liver Drug Fails in Late-Stage Trials
Bausch Health said its experimental liver treatment did not meet goals in Phase 3 trials, sending shares lower in early trading.
Oppenheimer Starts Coverage on Coherus Oncology With Bullish Outlook
Oppenheimer initiates coverage of Coherus Oncology with an Outperform rating and a $10 price target, highlighting promising cancer drug programs and key clinical data expected in 2026.